Thymalin

Thymalin is a polypeptide complex originally extracted from the thymus gland of calves, developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. As one of the first peptide bioregulators characterized, thymalin demonstrated the concept that organ-derived peptide extracts could restore function to aging or damaged immune systems. Thymalin contains a mixture of small peptides (primarily dipeptides and tripeptides) that collectively restore T-cell immunity, normalize the T-helper/T-suppressor cell ratio, and enhance thymic function. Over 30 years of clinical use in Russia have demonstrated its ability to restore immune competence in immunodeficient patients, reduce infection rates, and potentially extend lifespan — a 6-year clinical study in elderly patients showed 2-fold reduction in mortality compared to controls.

Thymalin acts on T-cell precursors and mature T-cells to restore immune function. It promotes thymocyte differentiation into mature CD4+ and CD8+ T-cells, normalizes the CD4/CD8 ratio, and enhances T-cell proliferative responses to antigens. It modulates cytokine production — enhancing IL-2 and IFN-γ while normalizing TNF-α — shifting toward balanced Th1/Th2 responses. Thymalin also enhances NK cell activity and phagocytic function of macrophages and neutrophils.

Immune Restoration Thymalin is used clinically in Russia for immunodeficiency states, including post-surgical immune suppression, chronic infections, and age-related immunosenescence. Studies show restoration of T-cell counts, improved vaccine responses, and reduced infection frequency. Aging and Longevity The landmark Khavinson clinical study (2003) followed elderly patients treated with thymalin + epithalon for 6 years, demonstrating 2-fold reduction in mortality, improved organ function, and enhanced quality of life compared to untreated controls. Cancer Immunotherapy Adjunct Used as an immune adjuvant alongside chemotherapy and radiation in Russian oncology practice, showing improved immune reconstitution and reduced infectious complications.

T-cell receptor signaling enhancement. IL-2/STAT5 pathway for T-cell proliferation. Thymic stromal cell stimulation for thymocyte maturation. NF-κB modulation for cytokine balance.

Generally well-tolerated over decades of clinical use. Rare allergic reactions. Mild injection site pain. No significant adverse effects documented in clinical studies spanning thousands of patients.

Thymalin is supplied as a lyophilized powder for injection (10 mg vials). Store at 2-8°C. Shelf life 3 years. Reconstitute with isotonic saline before intramuscular injection. Typical course: 5-10 mg daily for 5-10 days.

Approved in Russia and several CIS countries as an immunomodulatory medication. Not approved by FDA or EMA. Classified as a research peptide in Western countries.